Navigation Links
David Lichtenstein: Biotechnology is Rich Area for Investment
Date:10/30/2012

NEW YORK, Oct. 30, 2012 /PRNewswire/ -- As many scientists and researchers are aware, biology entails an incredibly complex series of mechanisms and processes that still amaze intelligent minds today. While these biological systems have shaped the world, the application of modern biotechnology has only existed for approximately for three decades. According to a recent FundWeb article, this year marks the 30th anniversary of the "first biotechnology drug approved for human medical use," known as Humulin, "a genetically engineered version of natural human insulin for the treatment of diabetes." Since 1982, biotechnology has seeped its way into modern science and popular applications, which has led many to believe that biotechnology is the next "technology super-cycle." David Lichtenstein, biotechnology supporter and BrainStorm Cell Therapeutics investor, agrees that the science certainly holds the potential to change culture and the way humans live and solve problems.

David Lichtenstein states, "It is amazing to look back at the last 30 years — a small period in terms of scientific development — and realize just how far biotechnology has come. I expect these applications to become more present in our society, improving every facet of daily life." According to the article, such varied use of biotechnology has been witnessed since the original introduction of Humulin. It states, "Roughly two-thirds of all new drugs approved by the FDA have been discovered and/or developed by a biotechnology company at some stage." In addition to medical use, biotechnology has encouraged significant changes in agriculture and industrial manufacturing."

According to the article, financial analysts believe that biotechnology holds the potential for creating the next major socio-economic era in modern culture. It explains that such possibility for growth opens up a wide variety of investment opportunities in biotechnology. However, few have committed to investing in the science. Having already made significant investments in the field of biotechnology, David Lichtenstein knows that the industry holds promise. At BrainStorm Cell Therapeutics alone, there are projects that focus on repairing ALS, Multiple Sclerosis and Parkinson's disease through stem cell therapy.

David Lichtenstein concludes, "As far as investment strategies go, biotechnology is one field that is new, exciting and offers opportunity for long-term profit. After close examination, I believe wary investors may change their mind about investing in this incredible field of science."

ABOUT:

David Lichtenstein is a supporter of the growth of biotechnology and has become a major investor in the innovative science. He is currently an investor in BrainStorm Cell Therapeutics, a biotechnology company that develops adult stem cell therapies to resolve medical issues associated with severe neurodegenerative disorders including ALS, Multiple Sclerosis and Parkinson's disease. In addition, David Lichtenstein has proven his worth as an investment strategist, having steadily built the Lightstone Group since 1988. As chairman and CEO of the Lightstone Group, David Lichtenstein has carefully developed a diverse portfolio of properties allowing the company to become of the most widespread and successful privately held real estate companies in the United States of America.

 


'/>"/>
SOURCE David Lichtenstein
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Renowned Operations and Supply Chain Expert Dr. David Simchi-Levi Joins OPS Rules
2. Maine Center for Creativity Selects Glenn Close and David Shaw to Receive Inaugural Maine Creative Industry Award
3. China Biologic Products Names Chairman David Gao to Additional Post of CEO
4. Dr. David L. Blecker MD, MPH, F.A.C.P. Joins Inergetics Advisory Board to Co-Develop and Market Products to Penetrate Nephrology Market
5. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
6. Germany Prioritizes Medical Biotechnology with New Initiatives
7. Biomass characterization technology research highlighted in Industrial Biotechnology journal
8. Bolder BioTechnology Announces Publication of Data Demonstrating Utility of the Companys Long-Acting IL-11 Analog to Prevent Renal Ischemia Reperfusion Injury
9. Global Marine Biotechnology Industry
10. Verenium Corporation And Alexandria Real Estate Equities, Inc. Celebrate The Grand Opening Of A New State-of-the-art Biotechnology Facility
11. India Biotechnology in India Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... (PRWEB) , ... April 18, 2017 , ... ... Halo Labs . The move comes after the company changed focus to ... market, our new brand and our new technology,” says CEO Robert Hart. Founders ...
(Date:4/19/2017)... ... April 19, 2017 , ... ... financing round. This event adds to several other early achievements at ThermaGenix, including ... Scientific Teams. , ThermaGenix will use proceeds from the Series A-1 ...
(Date:4/19/2017)... (PRWEB) , ... April 19, 2017 , ... ... Event, which makes educational webinars accessible to novices as well as experienced ... preanalytical variables of commonly performed coagulation screening tests. , Hemostasis testing quality ...
(Date:4/19/2017)... , April 19, 2017  As a ... and Heroin Summit ,  Proove® Biosciences, Inc. ... genetics, environmental, and lifestyle factors to accurately predict ... University of Southern California (USC), the Interventional Pain ... Proove publish results showing that Proove Opioid Risk® ...
Breaking Biology Technology:
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, ... Simple," and 23andMe , the leading personal genetics ... choices.  Zipongo can now provide customers with personalized nutrition ... goals and biometrics, but also genetic markers impacting how ... Zipongo,s personalized food decision support platform uses biometrics ...
(Date:3/7/2017)... , March 7, 2017   HireVue , the ... global companies identify the best talent, faster, today announced ... Sales Officer (CSO) and Diana Kucer as ... out a seasoned executive team poised to drive continued growth ... on a year of record bookings in 2017. ...
(Date:3/2/2017)... 2, 2017 Summary This report provides ... its partnering interests and activities since 2010. ... Read the full report: ... since 2010 report provides an in-depth insight into the partnering ... On demand company reports are prepared upon purchase ...
Breaking Biology News(10 mins):